Yet the DEA has stated unequivocally that it considers CBD to be illegal under the Controlled Substances Act. “CBD derived from the cannabis plant is controlled under Schedule I of the CSA because it is a naturally occurring constituent of marijuana,” Joseph Rannazzisi, the deputy assistant administrator of the DEA, told a congressional panel in June. “While there is ongoing research into a potential medical use of CBD, at this time, CBD has no currently accepted medical use in the USA.” Moreover, DEA spokesman Eduardo Chavez told the New Republic that Medical Marijuana, Inc.’s in-house opinion with regards to CBD has no merit. “The bottom line,” Chavez said, “is the oil is part of the marijuana plant, and the marijuana plant is currently a Schedule I controlled substance under federal law.”
Fig. 5. Typical architecture of categories of cultivated Cannabis sativa. Top left: narcotic plants are generally low, highly branched, and grown well-spaced. Top right: plants grown for oilseed were traditionally well-spaced, and the plants developed medium height and strong branching. Bottom left: fiber cultivars are grown at high density, and are unbranched and very tall. Bottom center: “dual purpose” plants are grown at moderate density, tend to be slightly branched and of medium to tall height. Bottom right: some recent oilseed cultivars are grown at moderate density and are short and relatively unbranched. Degree of branching and height are determined both by the density of the plants and their genetic background.
Best CBD Oil
Over the past two years, 17 states have passed laws legalizing CBD so that patients can obtain the drug without fear of prosecution from local authorities. For intractable childhood epilepsies—the sorts of seizure disorders that for centuries have ruined lives and shattered families, the ones even specialists like Hernandez dread—CBD could be a miracle cure.
These CBD-only laws also attempt to impose some regulation on CBD oils, such as establishing how much CBD and THC such products must contain. For example, on June 1, the day I sat down with Hernandez in Fort Worth, Texas, Governor Greg Abbott signed the state’s Compassionate Use Act into law in Austin. The law requires that all CBD products contain no more than 0.5 percent THC and at least 10 percent CBD. However, the bill does not specify how the state plans to enforce this requirement. The law contains no language outlining how laboratories can test CBD products, what kinds of standards they would use, or who would regulate them.
Recreational cannabis use centers around one chemical: the psychoactive cannabinoid tetrahydrocannabinol (THC). Consuming this chemical induces euphoric and stimulating sensations commonly referred to as a “high.” For most marijuana users, these sensations are pleasurable and enjoyable. For some, however, THC can induce feelings of anxiety and paranoia, especially in large doses.
Cannabidiol has been found to act as an antagonist of GPR55, a G protein-coupled receptor and putative cannabinoid receptor that is expressed in the caudate nucleus and putamen in the brain. It has also been found to act as an inverse agonist of GPR3, GPR6, and GPR12. Although currently classified as orphan receptors, these receptors are most closely related phylogeneticaly to the cannabinoid receptors. In addition to orphan receptors, CBD has been shown to act as a serotonin 5-HT1A receptor partial agonist, and this action may be involved in its antidepressant, anxiolytic, and neuroprotective effects. It is an allosteric modulator of the μ- and δ-opioid receptors as well. The pharmacological effects of CBD have additionally been attributed to PPARγ agonism and intracellular calcium release.
One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of tumors. During this 2-year study, groups of mice and rats were given various doses of THC by gavage. A dose-related decrease in the incidence of hepatic adenoma tumors and hepatocellular carcinoma (HCC) was observed in the mice. Decreased incidences of benign tumors (polyps and adenomas) in other organs (mammary gland, uterus, pituitary, testis, and pancreas) were also noted in the rats. In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis lung adenocarcinoma cells in vitro and in vivo . In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.[5-8]
In addition to acting on the brain, CBD influences many body processes. That’s due to the endocannabinoid system (ECS), which was discovered in the 1990s, after scientists started investigating why pot produces a high. Although much less well-known than the cardiovascular, reproductive, and respiratory systems, the ECS is critical. “The ECS helps us eat, sleep, relax, forget what we don’t need to remember, and protect our bodies from harm,” Marcu says. There are more ECS receptors in the brain than there are for opioids or serotonin, plus others in the intestines, liver, pancreas, ovaries, bone cells, and elsewhere.
We gave the highest points to companies that use a CBD distillate for their tinctures. The process of distillation creates an extract that is pure on a molecular level. There are people who think distillate is too pure, and that a full spectrum decarb produces a more effective tincture. But in light of the inconclusive evidence, we prefer a distillate. The process allows for a high degree of control as to the finished product. It’s also odorless and tasteless, so those tinctures tend to taste better.
Pain management improves a patient’s quality of life throughout all stages of cancer. Through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists, the mechanisms of cannabinoid-induced analgesia have been analyzed.[Level of evidence:1iC] The CB1 receptor is found in the central nervous system (CNS) and in peripheral nerve terminals. CB2 receptors are located mainly in peripheral tissue and are expressed in only low amounts in the CNS. Whereas only CB1 agonists exert analgesic activity in the CNS, both CB1 and CB2 agonists have analgesic activity in peripheral tissue.[48,49]